{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061105","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.036782+00:00","generated_at":"2026-06-08T09:06:09.488701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Assembly Biosciences reports Q3 net loss $14.4M; partnership with Gilead provides $100M upfront","bullets":["Net loss $14.4M ($0.27/sh) vs $23.1M ($0.48/sh) in Q3 2022.","R&D expenses fell to $10.8M from $18.1M YoY due to trial completions and pipeline discontinuations.","Cash $46.2M at Sep 30; $100M upfront from Gilead in Oct extends cash runway into 2H 2025.","Partnership with Gilead includes opt-in rights on current/future pipeline; Gilead contributed two herpesvirus programs.","Appointed Anuj Gaggar, MD, PhD as CMO; expects four development candidates in clinic by end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061105","json":"https://secwatch.observer/filing/0000950170-23-061105.json","markdown":"https://secwatch.observer/filing/0000950170-23-061105.md","text":"https://secwatch.observer/filing/0000950170-23-061105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/0000950170-23-061105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/asmb-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:06:09.488701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"87dd04b2458c5ceee79c2eb7328eda822ec784cc","claim":"ASSEMBLY BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income Net loss attributable to common stockholders was $14.4 million, or $0.27 per basic and diluted share.","evidence_excerpt":"Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426800/000095017023061105/0000950170-23-061105-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders was $14.4 million, or $0.27 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}